Ukraine proposes $100 bln US weapons deal for security guarantees - FT
Calvin Sandra, Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), recently sold 3,348 shares of common stock. The sale, executed on February 3, 2025, was at a price of $20.12 per share, totaling approximately $67,361. This transaction was conducted to cover tax withholding obligations related to the settlement of vested restricted stock units, as mandated by the company’s equity incentive plans. Following this sale, Sandra retains ownership of 63,654 shares in the company. The transaction comes as Travere’s stock trades near its 52-week high of $21.56, having delivered an impressive 155% return over the past year.
Additionally, on January 31, 2025, Sandra acquired 13,000 shares of common stock at no cost, increasing her total holdings to 67,002 shares prior to the subsequent sale. This acquisition was part of a restricted stock unit grant, which entitles her to receive one share of common stock per unit. With a current market capitalization of $1.84 billion, InvestingPro analysis reveals analyst targets ranging from $18 to $45 per share, suggesting significant potential volatility ahead. For deeper insights into Travere’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Travere Therapeutics, Inc. has announced plans to conduct a public offering of its common stock, with Jefferies and Leerink Partners managing the offering as joint book-running managers. The biopharmaceutical company, known for its focus on treatments for rare diseases, will also provide underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The specifics of the offering, including its completion, timing, and size, are subject to market and other conditions. The shares will be offered pursuant to an automatic shelf registration statement filed and effective with the Securities and Exchange Commission (SEC). Notably, Travere has not yet disclosed the intended use of the proceeds from the offering. These developments are recent, and as with any forward-looking statements, they are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.